surovatamig

Surovatamig is a fully human IgG4 bispecific monoclonal antibody that acts as a T-cell engager, targeting both **CD19** on malignant B cells and **CD3** on cytotoxic T lymphocytes. By binding simultaneously to CD19 and CD3, it redirects and activates cytotoxic T cells to kill malignant B cells. Surovatamig is engineered to bind CD3 with lower affinity than some previous T-cell engagers, which is intended to reduce risks such as excessive cytokine release and neurotoxicity. It is being developed primarily for the treatment of **relapsed or refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL)** after two or more prior therapies in both adolescents and adults, but is also in clinical trials for other B-cell malignancies including follicular lymphoma and non-Hodgkin lymphoma. It is administered intravenously or subcutaneously. The drug was originally developed by TeneoTwo and TeneoBio and is currently being developed by AstraZeneca[1][2][3][4][5][7].

Brand names

surovatamig

Other names

AZD0486AZD-0486AZD 0486TNB-486TNB486TNB 486